These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 9384552)

  • 1. Neurobiology of schizophrenia.
    Egan MF; Weinberger DR
    Curr Opin Neurobiol; 1997 Oct; 7(5):701-7. PubMed ID: 9384552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC
    Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular brain imaging and the neurobiology and genetics of schizophrenia.
    Heinz A; Romero B; Gallinat J; Juckel G; Weinberger DR
    Pharmacopsychiatry; 2003 Nov; 36 Suppl 3():S152-7. PubMed ID: 14677072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synaptic dysfunction in schizophrenia.
    Yin DM; Chen YJ; Sathyamurthy A; Xiong WC; Mei L
    Adv Exp Med Biol; 2012; 970():493-516. PubMed ID: 22351070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thalamic dysfunction in schizophrenia: neurochemical, neuropathological, and in vivo imaging abnormalities.
    Clinton SM; Meador-Woodruff JH
    Schizophr Res; 2004 Aug; 69(2-3):237-53. PubMed ID: 15469196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurobiological background of negative symptoms.
    Galderisi S; Merlotti E; Mucci A
    Eur Arch Psychiatry Clin Neurosci; 2015 Oct; 265(7):543-58. PubMed ID: 25797499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of cognitive deficits associated with schizophrenia: potential role of catechol-O-methyltransferase inhibitors.
    Apud JA; Weinberger DR
    CNS Drugs; 2007; 21(7):535-57. PubMed ID: 17579498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine modulation of emotional processing in cortical and subcortical neural circuits: evidence for a final common pathway in schizophrenia?
    Laviolette SR
    Schizophr Bull; 2007 Jul; 33(4):971-81. PubMed ID: 17519393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopaminergic control of working memory and its relevance to schizophrenia: a circuit dynamics perspective.
    Tanaka S
    Neuroscience; 2006 Apr; 139(1):153-71. PubMed ID: 16324800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Schizophrenia: from phenomenology to neurobiology.
    Wong AH; Van Tol HH
    Neurosci Biobehav Rev; 2003 May; 27(3):269-306. PubMed ID: 12788337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The neurobiology of schizophrenia.
    Littrell RA; Schneiderhan M
    Pharmacotherapy; 1996; 16(6 Pt 2):143S-147S; discussion 166S-168S. PubMed ID: 8947997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular mechanisms underlying glutamatergic dysfunction in schizophrenia: therapeutic implications.
    Gaspar PA; Bustamante ML; Silva H; Aboitiz F
    J Neurochem; 2009 Nov; 111(4):891-900. PubMed ID: 19686383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracellular signaling and approaches to the treatment of schizophrenia and associated cognitive impairment.
    Snyder GL; Vanover KE
    Curr Pharm Des; 2014; 20(31):5093-103. PubMed ID: 24345266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Animal models of working memory: insights for targeting cognitive dysfunction in schizophrenia.
    Castner SA; Goldman-Rakic PS; Williams GV
    Psychopharmacology (Berl); 2004 Jun; 174(1):111-25. PubMed ID: 15205882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Role of astrocytes in alterations of glutamatergic neurotransmission in schizophrenia].
    Kolomeets NS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(1):110-117. PubMed ID: 25945378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primate phencyclidine model of schizophrenia: sex-specific effects on cognition, brain derived neurotrophic factor, spine synapses, and dopamine turnover in prefrontal cortex.
    Elsworth JD; Groman SM; Jentsch JD; Leranth C; Redmond DE; Kim JD; Diano S; Roth RH
    Int J Neuropsychopharmacol; 2014 Oct; 18(6):. PubMed ID: 25522392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Genetic and pharmacological effects on prefrontal cortical function in schizophrenia].
    Heinz A; Braus DF; Romero B; Gallinat J; Puls I; Juckel G; Weinberger DR
    Nervenarzt; 2004 Sep; 75(9):845-56. PubMed ID: 15372159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Schizophrenia: from dopaminergic to glutamatergic interventions.
    Laruelle M
    Curr Opin Pharmacol; 2014 Feb; 14():97-102. PubMed ID: 24524997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neural basis of psychosis-related behaviour in the infection model of schizophrenia.
    Meyer U; Feldon J
    Behav Brain Res; 2009 Dec; 204(2):322-34. PubMed ID: 19154759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PDE Inhibitors for the Treatment of Schizophrenia.
    Snyder GL; Vanover KE
    Adv Neurobiol; 2017; 17():385-409. PubMed ID: 28956340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.